Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | MDM2 amp TP53 wild-type |
Therapy | Alrizomadlin |
Indication/Tumor Type | liposarcoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
MDM2 amp TP53 wild-type | liposarcoma | predicted - sensitive | Alrizomadlin | Case Reports/Case Series | Actionable | In a Phase I trial, Alrizomadlin (APG-115) treatment demonstrated safety in patients with advanced solid tumors, with an overall response rate of 10% (2/20, partial responses) and stable disease in 50% (10/20) of evaluable patients and a median progression-free survival (PFS) of 6.1 months, with an overall response rate of 25% (2/8) and disease control rate of 100% (8/8) in liposarcoma patients with wild-type TP53 and MDM2 amplification (PMID: 39002360). | 39002360 |
PubMed Id | Reference Title | Details |
---|---|---|
(39002360) | A first-in-human phase I study of a novel MDM2/p53 inhibitor alrizomadlin in advanced solid tumors. | Full reference... |